Abstract:Puerarin is a potential therapeutic agent for cardiovascular diseases. But its poor oral bioavailability restricts Its clinical application. In present study, as an evaluation of a formulation to improve the bioavailability of the drug, puerarin and its phospholipid complex were given to rats by intragastrically (i.g.) administration to compare pharmacokinetic, tissue distribution, and excretion. Serum samples were obtained at designated times after a single oral dose of 400 mg/kg puerarin or its complex. Tissue samples (heart, liver, spleen, kidney, lung, and brain), urine, and feces were collected and analyzed by a sensitive and specific high. performance liquid chromatography (HPLC) method after i.g. administration of puerarin or its phospholipid complex. Compartmental and non-compartmental analyses were applied to the serum concentration versus time data. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. An open two-compartment, first-order model was selected for pharmacokinetic modeling. The results showed that after i.g. administration of 400 mg/kg puerarin and its phospholipid complex (equivalent to 400 mg/kg of puerarin), the pharmacokinetic parameters of the two formulations were different. The serum concentrations reached peaks at 0.894 +/- 0.521 h and 0.435 +/- 0.261 h, respectively, indicating the complex was more readily absorbed in serum than puerarin. The maximum concentrations for puerarin and its complex were 1.367 +/- 0.586 mg.L-1 and 2.202 +/- 1.28 mg.L-1 and AUC were 5.779 +/- 1.662 mg.h. L-1 and 8.456 +/- 0.44 mg.h L-1, respectively, indicating a higher bioavailability for the complex. The widely distribution characteristics of puerarin and its complex in tissues post-i.g. administration was identical and in a descending order as follows: lung, kidney, liver, heart, spleen, and brain. However, the amount was different. Puerarin distribution was higher in heart, lung, and brain after administering the complex. The cumulative 72 h urinary excretion of puerarin after i.g. administration of puerarin and its complex accounted for 1.05%, 1.11% of the administered dose, respectively. The cumulative feces excretion of puerarin was 32.3% and 25.5%. To sum up, oral administration of puerarin phospholipid complex modified the pharmacokinetics and tissue distribution of puerarin and it could be an effective oral formulation for puerarin.

Improvement in Solubility and Bioavailability of Puerarin by Mechanochemical Preparation

Solubilization on Puerarin by Hydroxypropropyl-Β-cyclodextrin and Preparation of Their Inclusion Compound

Preparation, characterization and bioavailability of oral puerarin nanoparticles by emulsion solvent evaporation method

Enhancing the bioaccessibility of puerarin through the collaboration of high internal phase Pickering emulsions with β-carotene

Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles

Study on the dissolution rate and bioavailability of Radix Pueraria micropowder prepared by super fine crushing process

Enhancing the Physiochemical Properties of Puerarin via L-Proline Co-Crystallization: Synthesis, Characterization, and Dissolution Studies of Two Phases of Pharmaceutical Co-Crystals

Pharmacokinetic, Tissue Distribution, and Excretion of Puerarin and Puerarin-Phospholipid Complex in Rats

Formulation and Pharmacokinetics Evaluation of Puerarin Nanocrystals for Intravenous Delivery

Recent Advances in Methods of Puerarin Biotransformation.

Whole-cell catalytic synthesis of puerarin monoesters and analysis of their antioxidant activities.

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat.

Comparative Physicochemical Characterization of Phospholipids Complex of Puerarin Formulated by Conventional and Supercritical Methods

Puerarin-Na Chelate Hydrate Simultaneously Improves Dissolution and Mechanical Behavior

Preparation of Solid Dispersion of Polygonum Cuspidatum Extract by Hot Melt Extrusion to Enhance Oral Bioavailability of Resveratrol

Characterization and evaluation of self-microemulsifying sustained-release pellet formulation of puerarin for oral delivery.

Study of Hydroxypropyl β-Cyclodextrin and Puerarin Inclusion Complexes Encapsulated in Sodium Alginate-Grafted 2-Acrylamido-2-Methyl-1-Propane Sulfonic Acid Hydrogels for Oral Controlled Drug Delivery

Enhanced Bioaccessibility of Microencapsulated Puerarin Delivered by Pickering Emulsions Stabilized with OSA-Modified Hydrolyzed Pueraria montana Starch: In Vitro Release, Storage Stability, and Physicochemical Properties

[Inhibition of Transformation from Puerarin Monohydrate to Puerarin Dihydrate by Polyvinylpyrrolidones During Dissolution].

Preparation of Liposomes Encapsulating Puerarin-Cyclodextrin Complexes and Its Pharmaceutical Characteristics in Vitro